Kyowa Hakko licensed to BioWa (wholly owned subsidiary in US)
30 July 2007
Kyowa Hakko licensed to BioWa (wholly owned subsidiary in US), a novel antibody engineering technology (COMPLEGENTTM) for the efficacy enhancement of therapeutic antibodies
Kyowa Hakko Kogyo has developed and licensed to BioWa (a wholly owned subsidiary in US...
Kyowa Hakko Three-month Net Sales up 10.8%; Raises profit forecasts
30 July 2007
Tokyo, July 27, 2007-- Kyowa Hakko Kogyo Co., Ltd. (Kyowa Hakko) TOKYO today announced its first quarter financial results for the three-month period ended June 30, 2007. Consolidated net sales were Yen 94.9 billion, an increase of Yen 9.2 billion, or 10...
Tokyo, April 27, 2007 --- Kyowa Hakko Kogyo Co. Ltd. (Kyowa Hakko) today announced its consolidated financial results for the year ended March 31, 2007 (Fiscal 2006). Consolidated operating income was Yen 30.6 billion, an increase of 20.2% compared to fiscal 2005, and ahead o...
Submission of New Drug Application for Istradefylline(KW-6002), an investigational anti-Parkinson’s disease drug
27 April 2007
Kyowa Hakko Kogyo Co., Ltd. (President: Dr. Yuzuru Matsuda) announced that Kyowa Pharmaceutical, Inc. (New Jersey, United States, President: Shigeru Kobayashi), its wholly owned U.S subsidiary, submitted on April 25, 2007 a new drug application (NDA) to the U.S. Food and Drug Administration (...
Kyowa Hakko in-licenses ARQ 197, an anticancer agent in clinical development, from the US company ArQule
27 April 2007
On April 27, 2007, Kyowa Hakko Kogyo Co., Ltd. based in Tokyo, Japan (President and CEO: Dr. Yuzuru Matsuda) entered into a license agreement with the US drug development company ArQule based in Massachusetts, US (President and CEO: Dr. Stephen A. Hill), whereby Kyowa Hakko will b...
Tokyo, January 29. 2007-- Kyowa Hakko Kogyo Co., Ltd. (Kyowa Hakko) (TOKYO: 4151) today announced its third quarter financial results for the nine-month period from April 1, 2006 to December 31, 2006. Consolidated net sales for the period were Yen 268.1 billion, a decline of 1.5% compared to ...
Pie de imprenta